Duspatal

Quick links to important sections

Duspatal

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duspatal

What is Duspatal?

Duspatal is a medication primarily used to treat symptoms associated with functional gastrointestinal disorders. It belongs to a group of medicines known as antispasmodics, which are designed to act on the smooth muscles of the digestive tract.

Mechanism of Action

The active ingredient in Duspatal is mebeverine hydrochloride. It works by directly relaxing the smooth muscles of the gut wall. Unlike some other medications used for similar conditions, it achieves this effect without interfering with the normal movement (motility) of the intestines. By reducing muscle spasms and contractions, it helps alleviate the abdominal pain and discomfort often linked to digestive irregularities.

Therapeutic Use

This medication is typically used to manage the symptoms of Irritable Bowel Syndrome (IBS) and other related conditions characterized by intestinal spasms. These symptoms often include:

  • Abdominal pain and cramps
  • Persistent diarrhea or constipation (or alternating between both)
  • Flatulence and bloating

Because it focuses specifically on the muscle cells of the gastrointestinal tract, Duspatal is used to provide symptomatic relief from the localized distress caused by overactive gut musculature.

What side effects are possible with Duspatal?

Possible Side Effects and Safety Information

The official regulatory safety profile for mebeverine hydrochloride (Duspatal) primarily highlights risks related to allergic reactions (hypersensitivity) as documented in post-marketing surveillance by government health authorities.


Documented Adverse Reactions

Adverse reactions that have been spontaneously reported are classified into two primary system-organ classes:

  • Immune System Disorders
  • Skin and Subcutaneous Tissue Disorders

The specific effects documented include Urticaria (hives), Exanthema (skin rash), and Face oedema (swelling of the face). All listed adverse reactions are assigned the regulatory frequency classification of Not known, meaning a precise occurrence rate cannot be estimated from the available spontaneous post-marketing data.

Serious adverse reactions explicitly listed in official labeling include Angioedema (rapid and potentially severe swelling) and systemic Anaphylactic reactions (severe allergic reactions).


Population-Specific and General Safety Constraints

Safety Consideration Regulatory Statement
Paediatric Population Use is not recommended due to insufficient data regarding safety and efficacy.
Pregnancy and Lactation Not recommended during pregnancy or breast-feeding.
Renal/Hepatic Impairment No dosage adjustment is necessary; no specific risk identified.
Hypersensitivity The medicine is contraindicated if there is known hypersensitivity to the active substance or excipients.

Regulatory documentation confirms that the available safety data do not indicate any harmful effect on the ability to drive or operate machinery. Furthermore, studies have shown an absence of interaction between mebeverine and alcohol. Certain formulations may also contain excipients like lactose or sucrose, imposing a contraindication for individuals with specific hereditary sugar intolerances.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory guidance mandates that any individual suspecting an overdose of mebeverine hydrochloride (Duspatal) must talk to a doctor or go to a hospital straight away for immediate professional assessment.

Documented Overdose Profile

The officially documented clinical presentation in overdose situations is characterized by symptoms that are generally absent or mild and typically considered rapidly reversible. When manifestations have been observed, they have been classified as being of a neurological and cardiovascular nature. While the theoretical potential for CNS excitability may exist, specific severe or life-threatening complications are not commonly listed in the regulatory Overdose section.

Emergency Management

Treatment of an overdose is focused on symptomatic treatment, as regulatory documents explicitly state that no specific antidote is known. The official profile advises that measures to reduce drug absorption, such as activated charcoal, are usually considered unnecessary. However, the procedure of gastric lavage is described as conditionally relevant in specific situations: either in cases of multiple intoxication or if the intervention is initiated within about one hour of ingestion. The profile reinforces that immediate medical consultation is required for appropriate supportive management.

Therapeutic Uses of Duspatal

What Duspatal Treats: Main Uses and Benefits

The medication is applied across therapeutic domains where additional symptomatic support is needed, and generally contributes to easing the overall symptom load of distressing gastrointestinal manifestations. It is relevant within clinical settings that involve acute or disruptive symptom patterns.

It is commonly used across conditions characterized by periods of heightened symptoms such as Irritable Bowel Syndrome (IBS) and other chronic functional bowel disorders. Specifically, it is relevant for easing the severe, episodic abdominal pain and gripping cramps, as well as managing associated symptoms like persistent abdominal distension and bloating that are symptoms linked to organ-specific functional stress.

It is applied in scenarios where additional management of discomfort is required due to symptoms that interfere with daily functioning. This support helps address symptom clusters that may become intense or disruptive, providing symptomatic relief that contributes to improved comfort during these symptomatic periods.


Quick Fact: Support for Spasmodic Discomfort

Therapeutic Focus Symptoms Targeted Patient Benefit
Functional Gut Disorders Symptoms of increased neurological or muscular activity Helps patients cope more steadily with difficult episodes
Associated Discomfort Abdominal bloating and persistent distension Provides supportive relief when symptoms interfere with routine activities

Regulatory References

  1. NIH Systematic Review on Mebeverine Efficacy in IBS

Eligibility and Restrictions for Use

Official Eligibility Rules for Duspatal (Mebeverine)

The use of Duspatal is defined by specific population eligibility rules documented by regulatory authorities, which establish who is permitted to use the medicine and who is excluded or restricted.

Contraindications and Restrictions

Category Eligibility Status (Regulatory Language)
Absolute Contraindication Contraindicated in patients with known hypersensitivity to mebeverine hydrochloride or any excipients.
Excipient-Related Exclusion Must not be used by patients with rare hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
Pediatric Restriction Not recommended for use in children and adolescents below 18 years due to insufficient data on safety and efficacy for adult-strength formulations.

Use in Special Populations

Population Group Official Regulatory Status
Adults and Elderly Permitted for use at standard labeled doses. No dosage adjustment is deemed necessary for the elderly.
Renal/Hepatic Impairment No dosage adjustment is deemed necessary based on post-marketing data.
Pregnancy Not recommended due to limited or insufficient data.
Breastfeeding Should not be used as it is unknown if the medicine is excreted in human milk.

These guidelines define the official population boundaries for the medicine, prohibiting use for specific patient groups (hypersensitivity, metabolic disorders) and restricting use for individuals under 18 or those who are pregnant or breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the formally documented interaction profile of Mebeverine hydrochloride (Duspatal) based on regulatory authority statements.

Official Regulatory Interaction Profile

Regulatory documentation characterizes the interaction profile of Mebeverine by a lack of known, clinically relevant drug-drug interactions. The medicine is rapidly and extensively metabolized by esterases, a process that regulatory authorities anticipate results in low potential for interaction with other medicinal products.

Interaction Type Status According to Regulatory Documents
Drug–Drug Interactions None documented; none anticipated.
Contraindicated Combinations None formally listed.
Timing Separation Rules None required due to documented interactions.

Documented Interactions with Other Substances

The only substance for which a formal interaction study has been performed and explicitly documented in the official prescribing information is ethanol (alcohol). Studies confirmed the absence of any interaction between mebeverine hydrochloride and alcohol. No specific interactions are documented with food, herbal products, or dietary supplements.

Regulatory Context

Because no clinically significant interactions are anticipated, the official labeling does not specify any medicinal products that are prohibited for co-administration due to interaction risk. Furthermore, no population-specific interaction considerations are required for groups such as the elderly or patients with hepatic impairment.

Mechanism of Action

The mechanism of action of mebeverine, the active component in Duspatal, is that of a musculotropic antispasmodic acting directly on the smooth muscle fibers of the gastrointestinal (GI) tract. The primary mechanistic effect involves the modulation of ion channels within the muscle cell membrane. Specifically, mebeverine influences the flow of key ions, including calcium ( Ca^2+) and potassium ( K^+). By interfering with Ca^2+ influx and K^+ efflux, the compound modifies the cell's excitability and prevents the sustained electrical and biochemical activity required for excessive, unregulated contraction. This action exhibits a degree of selectivity for hyperactive contractile processes over basal muscle tone. Consequently, mebeverine alters the level of physiological muscle tone, thereby influencing the frequency and intensity of contractile events and supporting the preservation of underlying muscle activity.

Dosage and Administration Information

Instruction Map: How to use Duspatal

This map outlines the standardized, high-level usage principles for Mebeverine hydrochloride.


Administration Scope

Category Instruction Entity
Route of administration Oral use.
Dosing schedule 135 mg tablets: One tablet per dose, up to three times per day. 200 mg modified-release capsules: One capsule per dose, twice per day.
Timing in relation to meals Taken preferably 20 minutes before a meal.
Preparation requirements Must be swallowed whole with a sufficient amount of water (e.g., at least 100 ml).
Age-group administration rules Adults (18+): Standard regimens apply. Children/Adolescents (below 18): Use is generally not recommended due to insufficient data. Elderly: No dosage adjustment is typically required.
Missed-dose rules If a dose is missed, skip the missed dose and continue with the next one at the scheduled time; a double dose must not be taken.
Special procedural conditions The tablets/capsules must not be chewed. Dosage may be gradually reduced after symptoms have been controlled.

Instruction Classifications (High-Level)

Category Classification
Administration method type Oral
Frequency pattern Multiple times per day (BID or TID)
Administration Context Standardized oral protocol.
Use-context constraints Requires pre-meal timing; Not indicated for use in pediatric patients under 18.

Resulting Procedural Structure

Step sequence:

  • Take the prescribed oral dosage form (135 mg tablet or 200 mg capsule) at the designated frequency (two or three times daily).
  • Administer the dose preferably 20 minutes before a meal.
  • Swallow the entire tablet or capsule whole with a drink of water, ensuring the dosage form is not chewed.

Connection to the overall use protocol:

The administration protocol involves the use of the oral route with a defined frequency (two or three times daily), dependent on the chosen dosage strength. Specific procedural instructions, such as taking the medicine whole before a meal, are followed to ensure proper administration and functional release of the active ingredient. The regimen is standardized for adults, with no need for adjustment in the elderly or those with hepatic or renal impairment, defining a clear pattern for its use.

Recent Clinical Evidence

Evidence for Use in Irritable Bowel Syndrome (IBS)

Mebeverine was studied for Irritable Bowel Syndrome (IBS) and related functional bowel disorders using short-term, placebo-controlled Randomized Controlled Trials (RCTs) and subsequent systematic reviews. The primary research focused on adult patients with conditions characterized by fluctuating or episodic manifestations such as pain and cramping. Studies monitored patient-reported outcomes related to perceived discomfort and systemic functional imbalance. These outcomes included global measures of perceived symptom change and specific measurements of abdominal pain, cramping, bloating, and abdominal distension.

The findings describe patterns observed in the adult populations over short periods. However, when combined into high-level evidence summaries, the findings were mixed regarding overall global symptom change compared to placebo, reflecting variability across different research settings. This inconsistency contributes to the overall categorization of the evidence level being Moderate for adult IBS, acknowledging the existence of RCTs but noting the conflicts in high-level analyses.

The Landscape in Adolescents and Research Gaps

Evidence was also explored in a specific patient population: adolescents (12 to 17 years old) with IBS or Functional Abdominal Pain. Dedicated RCTs for this group used specific patient-reported outcomes, such as the study-defined measure of treatment success. Major trials reported that the symptom changes measured in the observed populations did not show distinct patterns compared to the control group, suggesting the available evidence is limited in distinguishing the pattern of reported changes from the pattern observed with an inactive substance. Consequently, the evidence for adolescents is currently rated as Low.

A critical limitation across the entire research record is the short follow-up duration, as evidence is primarily derived from settings evaluating only short-term symptom changes (typically 4 to 16 weeks). This means that long-term effects are not fully established, and there is limited information regarding the evolution of reported patterns over six months or one year. The inconsistency of findings for adult IBS also highlights that comparative evidence is lacking to fully clarify the symptomatic profile relative to placebo in all patients.

Key Studies & References

  1. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome

Frequently Asked Questions (FAQ)

Common questions about Duspatal (FAQ)


Q: What condition is Duspatal most commonly prescribed for?

According to official product information, the medicine is indicated for the symptomatic treatment of Irritable Bowel Syndrome (IBS). It is also used to address symptoms related to other functional bowel disorders, such as chronic irritable colon or mucous colitis.

Q: How does the action of Duspatal differ from a regular pain reliever?

Duspatal is classified as a musculotropic antispasmodic because it acts directly on the smooth muscle of the digestive tract. Its primary purpose is to relieve painful spasms (excessive cramping), unlike general pain relievers. Regulatory data indicates that this medicine is absent of certain systemic side-effects commonly seen with typical anticholinergics.

Q: Is Duspatal used for general stomach pain or only for specific types of digestive issues?

The medicine is specifically used to manage symptoms related to functional bowel disorders, such as colicky abdominal pain and cramping. Its action focuses on muscle spasms. It is not indicated for general, non-specific stomach pain that does not involve this type of spasmodic activity.

Q: How long does it typically take for Duspatal to begin having an effect?

Official patient information states that the active ingredient, mebeverine hydrochloride, typically starts to work after 1 hour following administration.

Q: What are the most common side effects listed in the official documents for Duspatal?

Official regulatory documents state the medicine is generally safe and well tolerated. Documented adverse reactions primarily relate to hypersensitivity (allergic reactions), such as rash, hives, or swelling. However, the exact frequency of these effects cannot be estimated from the available data.

Q: Is weight gain or weight loss noted as a possible side effect of Duspatal?

Official safety data does not indicate that the use of mebeverine hydrochloride causes either weight gain or weight loss as a documented side effect.

Q: Is Duspatal considered a narcotic or habit-forming medication?

According to regulatory data, the medicine is not classified as a narcotic. There are also no habit-forming tendencies reported.

Q: Can Duspatal be taken with over-the-counter cold and flu medicines or antibiotics?

Regulatory documentation notes there is a lack of known, clinically relevant drug-drug interactions with other medicinal products. Based on this, interactions with common medications like over-the-counter cold medicines or antibiotics are not anticipated.

Q: Is it typically safe to consume caffeine while taking Duspatal?

The official interaction profile states a lack of known, clinically relevant drug-drug interactions. Therefore, based on regulatory analysis, interactions with substances like caffeine are not anticipated.

Q: How is Duspatal eliminated from the body?

The medicine is metabolized completely by special enzymes called esterases, which break down the substance. The resulting breakdown products (metabolites) are then excreted nearly completely into the urine.

Q: What does the official documentation say about what happens if a person stops taking Duspatal suddenly?

The official product documentation states that dosage may be gradually reduced once symptoms are controlled. The documentation does not explicitly specify the effects or risks of sudden discontinuation.

Q: Where can I find the official patient information leaflet (PIL) for Duspatal?

Official patient information, such as the Patient Information Leaflet (PIL) or the Summary of Product Characteristics (SmPC), can be found on the websites of national regulatory agencies. These include agencies like the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA).

Q: Are there different brand names for the active ingredient in Duspatal in other countries?

Yes, the active ingredient, mebeverine hydrochloride, is marketed under various brand names in different countries. Examples of these alternative trade names include Colofac and Aurobeverine.

Q: Does the medicine contain any common allergens, like lactose or gluten?

Regulatory documents indicate that certain formulations contain the excipient lactose. This results in a contraindication for individuals with certain hereditary sugar intolerances. The official Summary of Product Characteristics does not explicitly list or mention gluten as an ingredient.

Q: What is the maximum recommended period of time for using Duspatal continuously?

The Summary of Product Characteristics states that the duration of use is not limited. Treatment can be stopped when symptoms are controlled and may be continued only during symptom flare-ups.

Q: Is Duspatal available without a prescription in some countries?

In some regions, mebeverine tablets may be available to purchase at a pharmacy without a prescription. This is typically limited to people seeking treatment for Irritable Bowel Syndrome (IBS) symptoms who have a prior formal diagnosis of IBS.

How should Duspatal be stored and disposed of?

Storage and Disposal of Duspatal (Mebeverine Hydrochloride)

Official Storage Conditions

Duspatal must be stored in a dry place at a temperature not greater than 30 C and protected from light. It is important that the medicine is kept in its original package and out of the sight and reach of children to comply with safety requirements. The medicine should not be frozen or refrigerated.

Disposal Instructions

Expired or unused Duspatal must not be disposed of in household waste or via wastewater. Official guidance requires that the product be discarded according to local regulatory procedures. Unused medicine should be returned to a pharmacist or a designated collection point to ensure proper environmental handling and avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duspatal found in:

A-Z Index: